Icon	Function
💬	A pop-up explanation appears when you mouse-over the text beside this icon. Also, an explanation window appears when you click this icon.
	The links beside this icon are links to external sites.
	Clicking this icon sorts the table by the item with this icon (Numerical or alphabetical order). Each click toggles between ascending and descending order.
	A text longer than 100 characters is fully displayed or collapsed.
	The contents of the displayed table are downloaded as a file named "table.csv".

DR info

Clinical trials : 40 / Drugs : 48 - (DrugBank : 11) / Drug target genes : 22 - Drug target pathways : 22

Drugs, Primary sponsors and Trial info (Enrollment year, Phase, Trial ID, Countries)

Acylated and unacylated ghrelin dosages
   University Hospital, Toulouse
      2021   -   NCT04768803   France
Aknemin 50
   Dra. Cristina Avendaño Solá
      2013   -   EUCTR2013-002154-67-ES   Spain
Alogabat
   Hoffmann-La Roche
      2023   Phase 2   NCT05630066   Australia;France;Germany;Italy;Spain;United States
Betaine
   University of California, San Diego
      2006   -   NCT00348933   United States
Blood collection
   Biogen
      2019   Early Phase 1   NCT04103333   United States
Carbidopa
   Boston Children’s Hospital
      2009   Phase 1   NCT00829439   United States
Creatine
   University of California, San Diego
      2006   -   NCT00348933   United States
Elliotts B® solution
   Ultragenyx Pharmaceutical Inc.
      2023   Phase 1;Phase 2   EUCTR2021-001793-36-FR   Australia;Canada;France;Germany;Israel;Spain;United Kingdom;United States
Elliotts B® solution (buffered intrathecal electrolyte/dextrose injection)product name: elliotts B® solutionproduct code: elliotts B® solutionpharmaceutical form: solution FOR injection
   Ultragenyx Pharmaceutical Inc.
      2023   Phase 1;Phase 2   EUCTR2021-001793-36-ES   Australia;Canada;France;Germany;Israel;Spain;United Kingdom;United States
Gaboxadol
   Ovid Therapeutics Inc.
      2019   Phase 3   NCT04106557   Australia;Germany;Israel;Netherlands;United States
Gaboxadol monohydrate 0.5 MG
   Ovid Therapeutics Inc.
      2020   Phase 3   EUCTR2019-004478-24-DE   Australia;Germany;Israel;Netherlands;United States
      -   Phase 3   EUCTR2019-004478-24-NL   Australia;Germany;Israel;Netherlands;United States
Gaboxadol monohydrate 0.5 MG capsule
   Ovid Therapeutics Inc.
      2020   Phase 3   EUCTR2019-002907-17-NL   Australia;Germany;Israel;Italy;Netherlands;United States
Gaboxadol monohydrate 2 MG
   Ovid Therapeutics Inc.
      2020   Phase 3   EUCTR2019-004478-24-DE   Australia;Germany;Israel;Netherlands;United States
      -   Phase 3   EUCTR2019-004478-24-NL   Australia;Germany;Israel;Netherlands;United States
Gaboxadol monohydrate 2 MG capsule
   Ovid Therapeutics Inc.
      2020   Phase 3   EUCTR2019-002907-17-NL   Australia;Germany;Israel;Italy;Netherlands;United States
Gaboxadol monohydrate 5 MG
   Ovid Therapeutics Inc.
      2020   Phase 3   EUCTR2019-004478-24-DE   Australia;Germany;Israel;Netherlands;United States
      -   Phase 3   EUCTR2019-004478-24-NL   Australia;Germany;Israel;Netherlands;United States
GTX-102
   Ultragenyx Pharmaceutical Inc
      2025   Phase 2   NCT07157254   Argentina;Brazil;France;Israel;Italy;Portugal;United Kingdom;United States
      2024   Phase 3   NCT06617429   Australia;Canada;Germany;Japan;Netherlands;Poland;Spain;United States
      2024   Phase 3   NCT06415344   Australia;Canada;France;Germany;Israel;Spain;United Kingdom;United States
      2020   Phase 1/Phase 2   NCT04259281   Australia;Canada;France;Germany;Israel;Spain;United Kingdom;United States
   Ultragenyx Pharmaceutical Inc.
      2023   Phase 1;Phase 2   EUCTR2021-001793-36-FR   Australia;Canada;France;Germany;Israel;Spain;United Kingdom;United States
      2023   Phase 1;Phase 2   EUCTR2021-001793-36-DE   Australia;Canada;France;Germany;Israel;Spain;United Kingdom;United States
GTX-102product code: GTX-102pharmaceutical form: solution FOR injectioninn or proposed INN: NOT availablecurrent sponsor code: GTX-102concentration unit: MG/ML milligram(S)/millilitreconcentration type: equalconcentration number: 11-
   Ultragenyx Pharmaceutical Inc.
      2023   Phase 1;Phase 2   EUCTR2021-001793-36-ES   Australia;Canada;France;Germany;Israel;Spain;United Kingdom;United States
ION582
   IONIS PHARMACEUTICALS, INC.
      2022   Phase 1;Phase 2   EUCTR2021-003009-23-IT   Argentina;Australia;Canada;France;Germany;Israel;Italy;Netherlands;Spain;United Kingdom;United States
   Ionis Pharmaceuticals, Inc.
      2025   Phase 3   NCT06914609   Australia;Canada;France;Germany;Israel;Italy;Japan;Poland;Singapore;South Korea;Spain;United Kingdom;United States
      2022   Phase 1;Phase 2   EUCTR2021-003009-23-FR   Argentina;Australia;Canada;France;Germany;Israel;Italy;Netherlands;Spain;United Kingdom;United States
      2021   Phase 1/Phase 2   NCT05127226   Australia;France;Israel;Italy;United Kingdom;United States
   Junge Candice
      2025   Phase 3   JPRN-jRCT2051250098   Argentina;Australia;Belgium;Canada;Colombia;Ireland;Israel;Italy;Japan;Poland;Singapore;South Korea;Spain;United Kingdom;United States
Levodopa
   Bennett Lavenstein
      2013   -   NCT03235037   -
   Boston Children’s Hospital
      2009   Phase 1   NCT00829439   United States
   Wen-Hann Tan
      2011   Phase 2/Phase 3   NCT01281475   United States
Lumbar puncture
   Biogen
      2019   Early Phase 1   NCT04103333   United States
Metafolin
   University of California, San Diego
      2006   -   NCT00348933   United States
Minocycline
   Puerta de Hierro University Hospital
      2014   Phase 2   NCT02056665   Spain
   University of South Florida
      2012   -   NCT01531582   United States
Minocycline hydrochloride
   Dra. Cristina Avendaño Solá
      2013   -   EUCTR2013-002154-67-ES   Spain
MVX-220
   MavriX Bio, LLC
      2025   Phase 1/Phase 2   NCT07181837   United States
NNZ-2591
   Neuren Pharmaceuticals Limited
      2022   Phase 2   NCT05011851   Australia
NON disponibile
   F. HOFFMANN - LA ROCHE LTD.
      2020   Phase 1   EUCTR2019-003787-48-IT   Canada;Italy;Netherlands;Spain;United Kingdom;United States
Nutritional formulation containing exogenous ketones
   University of Colorado, Denver
      2018   -   NCT03644693   United States
OV101
   Healx AI
      2019   Phase 3   NCT03882918   Israel;United States
   Ovid Therapeutics Inc.
      2020   Phase 3   EUCTR2019-004478-24-DE   Australia;Germany;Israel;Netherlands;United States
      2020   Phase 3   EUCTR2019-002907-17-NL   Australia;Germany;Israel;Italy;Netherlands;United States
      2017   Phase 1   NCT03109756   United States
      -   Phase 3   EUCTR2019-004478-24-NL   Australia;Germany;Israel;Netherlands;United States
OV101 regimen 1
   Healx AI
      2016   Phase 2   NCT02996305   Israel;United States
OV101 regimen 2
   Healx AI
      2016   Phase 2   NCT02996305   Israel;United States
RO7248824
   Hoffmann-La Roche
      2021   Phase 1   NCT04863794   Netherlands
      2020   Phase 1   NCT04428281   Canada;Italy;Netherlands;Spain;United Kingdom;United States
RO7248824/F02-01
   F. HOFFMANN - LA ROCHE LTD.
      2020   Phase 1   EUCTR2019-003787-48-IT   Canada;Italy;Netherlands;Spain;United Kingdom;United States
RO7248824/F03-01 (diluent FOR RO7248824/F02-01
   F. Hoffmann-La Roche
      2020   Phase 1   EUCTR2019-003787-48-NL   Canada;Italy;Netherlands;Spain;United Kingdom;United States
      2020   Phase 1   EUCTR2019-003787-48-GB   Canada;Italy;Netherlands;Spain;United Kingdom;United States
Rugonersen
   OHB Pediatrics Ltd.
      2026   Phase 3   NCT07605429   -
   Oak Hill Bio Ltd
      2025   -   NCT07136454   -
Sham procedure
   OHB Pediatrics Ltd.
      2026   Phase 3   NCT07605429   -
SHAM-LP
   Ultragenyx Pharmaceutical Inc
      2024   Phase 3   NCT06617429   Australia;Canada;Germany;Japan;Netherlands;Poland;Spain;United States
Taurine
   Hospital of Fudan University at Xiamen
      2024   -   ChiCTR2400082614   China
Vitamin B12
   University of California, San Diego
      2006   -   NCT00348933   United States